Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Identifying appropriate outcomes to help evaluate the impact of the Canadian Guideline for Safe and Effective Use of Opioids for Non-Cancer Pain.

Allen M, Sproule B, MacDougall P, Furlan A, Murphy L, Borg Debono V, Buckley N.

BMC Anesthesiol. 2020 Jan 7;20(1):6. doi: 10.1186/s12871-020-0930-4.

2.

Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects.

Brands B, Mann RE, Wickens CM, Sproule B, Stoduto G, Sayer GS, Burston J, Pan JF, Matheson J, Stefan C, George TP, Huestis MA, Rehm J, Le Foll B.

Drug Alcohol Depend. 2019 Dec 1;205:107641. doi: 10.1016/j.drugalcdep.2019.107641. Epub 2019 Oct 18.

PMID:
31678833
3.

Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults.

Matheson J, Sproule B, Di Ciano P, Fares A, Le Foll B, Mann RE, Brands B.

Psychopharmacology (Berl). 2019 Oct 22. doi: 10.1007/s00213-019-05369-y. [Epub ahead of print]

PMID:
31637452
4.

A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.

Ling S, Mangaoil R, Cleverley K, Sproule B, Puts M.

Drug Alcohol Depend. 2019 Apr 1;197:168-182. doi: 10.1016/j.drugalcdep.2019.02.007. Epub 2019 Feb 15.

PMID:
30831429
5.

Pharmacy in the 21st century: Enhancing the impact of the profession of pharmacy on people's lives in the context of health care trends, evidence and policies.

Dolovich L, Austin Z, Waite N, Chang F, Farrell B, Grindrod K, Houle S, McCarthy L, MacCallum L, Sproule B.

Can Pharm J (Ott). 2018 Dec 25;152(1):45-53. doi: 10.1177/1715163518815717. eCollection 2019 Jan-Feb. No abstract available.

6.

A pharmacist framework for implementation of the Canadian Guideline for Opioids for Chronic Non-Cancer Pain.

Murphy L, Chang F, Dattani S, Sproule B.

Can Pharm J (Ott). 2019 Jan 3;152(1):35-44. doi: 10.1177/1715163518818200. eCollection 2019 Jan-Feb. No abstract available.

7.

Evaluating comparative effectiveness of psychosocial interventions for persons receiving opioid agonist therapy for opioid use disorder: protocol for a systematic review.

Rice DB, Hutton B, Poulin P, Sproule BA, Wolfe D, Moher D, Thavorn K, Garber G, Taha S, Porath A, Willows M, Esmaeilisaraji L, Yazdi F, Shea B, Skidmore B, Corace K.

BMJ Open. 2018 Oct 18;8(10):e023902. doi: 10.1136/bmjopen-2018-023902.

8.

Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario.

Guan Q, Sproule BA, Vigod SN, Cadarette SM, Greaves S, Martins D, Gomes T.

Addiction. 2019 Feb;114(2):268-277. doi: 10.1111/add.14453. Epub 2018 Oct 30.

PMID:
30276907
9.

Reply to Goulden et al.: Risk of Bias in Study of Varenicline and Cardiovascular Outcomes.

Gershon AS, Campitelli MA, Hawken S, Sproule BA, Selby P.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):691-692. doi: 10.1164/rccm.201804-0639LE. No abstract available.

PMID:
29708391
10.

Guidance on opioid tapering in the context of chronic pain: Evidence, practical advice and frequently asked questions.

Murphy L, Babaei-Rad R, Buna D, Isaac P, Murphy A, Ng K, Regier L, Steenhof N, Zhang M, Sproule B.

Can Pharm J (Ott). 2018 Feb 8;151(2):114-120. doi: 10.1177/1715163518754918. eCollection 2018 Mar-Apr. No abstract available.

11.

Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation.

Gershon AS, Campitelli MA, Hawken S, Victor C, Sproule BA, Kurdyak P, Selby P.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):913-922. doi: 10.1164/rccm.201706-1204OC.

PMID:
29260881
12.

Impact of large-scale distribution and subsequent use of free nicotine patches on primary care physician interaction.

Kushnir V, Sproule BA, Cunningham JA.

BMC Public Health. 2017 Jul 11;18(1):4. doi: 10.1186/s12889-017-4548-5. Erratum in: BMC Public Health. 2017 Sep 22;17 (1):736.

13.

Incorporating sex, gender and vulnerable populations in a large multisite health research programme: The Ontario Pharmacy Evidence Network as a case study.

Cooke M, Waite N, Cook K, Milne E, Chang F, McCarthy L, Sproule B.

Health Res Policy Syst. 2017 Mar 20;15(1):20. doi: 10.1186/s12961-017-0182-z.

14.

Mailed distribution of free nicotine patches without behavioral support: Predictors of use and cessation.

Kushnir V, Sproule BA, Cunningham JA.

Addict Behav. 2017 Apr;67:73-78. doi: 10.1016/j.addbeh.2016.12.008. Epub 2016 Dec 23.

PMID:
28039798
15.

Sex and gender-based analysis in pharmacy practice research: A scoping review.

McCarthy L, Milne E, Waite N, Cooke M, Cook K, Chang F, Sproule BA.

Res Social Adm Pharm. 2017 Nov;13(6):1045-1054. doi: 10.1016/j.sapharm.2016.11.007. Epub 2016 Nov 19. Review.

PMID:
27908657
16.

Impact of self-reported lifetime depression or anxiety on effectiveness of mass distribution of nicotine patches.

Kushnir V, Sproule BA, Zawertailo L, Selby P, Tyndale RF, Leatherdale ST, Cunningham JA.

Tob Control. 2016 Sep;26(5):526-533. doi: 10.1136/tobaccocontrol-2016-052994. Epub 2016 Aug 19.

PMID:
27543563
17.

Knowledge, Perceptions and Attitudes toward Chronic Pain and Its Management: A Cross-Sectional Survey of Frontline Pharmacists in Ontario, Canada.

Patel T, Chang F, Mohammed HT, Raman-Wilms L, Jurcic J, Khan A, Sproule B.

PLoS One. 2016 Jun 7;11(6):e0157151. doi: 10.1371/journal.pone.0157151. eCollection 2016.

18.

Assessing anhedonia in depression: Potentials and pitfalls.

Rizvi SJ, Pizzagalli DA, Sproule BA, Kennedy SH.

Neurosci Biobehav Rev. 2016 Jun;65:21-35. doi: 10.1016/j.neubiorev.2016.03.004. Epub 2016 Mar 6. Review.

19.

Approach to the pharmacological management of chronic pain in patients with an alcohol use disorder.

Murphy L, Ng KW, Su VCh, Woodworth-Giroux S, Levy TS, Sproule BA, Furlan AD.

J Pain Res. 2015 Nov 30;8:851-7. doi: 10.2147/JPR.S88900. eCollection 2015.

20.

Correlates of benzodiazepine use in major depressive disorder: The effect of anhedonia.

Rizvi SJ, Sproule BA, Gallaugher L, McIntyre RS, Kennedy SH.

J Affect Disord. 2015 Nov 15;187:101-5. doi: 10.1016/j.jad.2015.07.040. Epub 2015 Aug 21.

PMID:
26331683
21.

Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression.

Rizvi SJ, Quilty LC, Sproule BA, Cyriac A, Michael Bagby R, Kennedy SH.

Psychiatry Res. 2015 Sep 30;229(1-2):109-19. doi: 10.1016/j.psychres.2015.07.062. Epub 2015 Jul 26.

PMID:
26250147
22.

Evaluation of an Educational Program for Clinical Pharmacists to Conduct Standardized Assessments for Medication-Induced Movement-Related Disorders.

Spadaro A, Kellar J, Remington G, Sproule B, Al-Sukhni M, Chaiet A.

Can J Hosp Pharm. 2015 May-Jun;68(3):258-64. No abstract available.

23.

Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysis.

Gomes T, Juurlink D, Yao Z, Camacho X, Paterson JM, Singh S, Dhalla I, Sproule B, Mamdani M.

CMAJ Open. 2014 Oct 1;2(4):E256-61. doi: 10.9778/cmajo.20140027. eCollection 2014 Oct.

24.

Effectiveness of brief interventions as part of the Screening, Brief Intervention and Referral to Treatment (SBIRT) model for reducing the nonmedical use of psychoactive substances: a systematic review.

Young MM, Stevens A, Galipeau J, Pirie T, Garritty C, Singh K, Yazdi F, Golfam M, Pratt M, Turner L, Porath-Waller A, Arratoon C, Haley N, Leslie K, Reardon R, Sproule B, Grimshaw J, Moher D.

Syst Rev. 2014 May 24;3:50. doi: 10.1186/2046-4053-3-50. Review.

25.

Naltrexone may block euphoria-like placebo effect.

Samokhvalov AV, Gamaleddin I, Sproule B, Rehm J.

BMJ Case Rep. 2013 Aug 7;2013. pii: bcr2013010098. doi: 10.1136/bcr-2013-010098.

26.

SAFER-OPIOIDS: A structured approach to identifying key information and drug therapy problems in chronic noncancer pain patients using opioid therapy.

Murphy L, Isaac P, Kalvik A, Ng K, Su VC, Sproule B.

Can Pharm J (Ott). 2013 Jan;146(1):26-9. doi: 10.1177/1715163512472310. No abstract available.

27.

A markov model approach assessing the cost of illness of generalized anxiety disorder in Canada.

Bereza BG, Machado M, Papadimitropoulos M, Sproule B, Ravindran AV, Einarson TR.

Neurol Ther. 2012 Jun 7;1(1):1. doi: 10.1007/s40120-012-0001-y. eCollection 2012 Dec.

28.

Effectiveness of brief interventions as part of the screening, brief intervention and referral to treatment (SBIRT) model for reducing the non-medical use of psychoactive substances: a systematic review protocol.

Young MM, Stevens A, Porath-Waller A, Pirie T, Garritty C, Skidmore B, Turner L, Arratoon C, Haley N, Leslie K, Reardon R, Sproule B, Grimshaw J, Moher D.

Syst Rev. 2012 May 7;1:22. doi: 10.1186/2046-4053-1-22.

29.

Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia.

Hazra M, Uchida H, Sproule B, Remington G, Suzuki T, Mamo DC.

Psychiatry Clin Neurosci. 2011 Dec;65(7):676-8. doi: 10.1111/j.1440-1819.2011.02280.x.

30.

Decreasing the harms of prescription opioids: a case for pharmacists.

Sproule BA.

Drug Alcohol Rev. 2011 May;30(3):327-9. doi: 10.1111/j.1465-3362.2010.00270.x. Review. No abstract available.

PMID:
21545565
31.

The psychological impact of a cancer diagnosed during pregnancy: determinants of long-term distress.

Henry M, Huang LN, Sproule BJ, Cardonick EH.

Psychooncology. 2012 Apr;21(4):444-50. doi: 10.1002/pon.1926. Epub 2011 Mar 2.

PMID:
21370310
32.

Effectiveness of pharmacist counseling combined with nicotine replacement therapy: a pragmatic randomized trial with 6,987 smokers.

Costello MJ, Sproule B, Victor JC, Leatherdale ST, Zawertailo L, Selby P.

Cancer Causes Control. 2011 Feb;22(2):167-80. doi: 10.1007/s10552-010-9672-9. Epub 2010 Dec 12.

PMID:
21153694
33.

The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol - a randomized study.

Dart RC, Green JL, Kuffner EK, Heard K, Sproule B, Brands B.

Aliment Pharmacol Ther. 2010 Aug;32(3):478-86. doi: 10.1111/j.1365-2036.2010.04364.x. Epub 2010 May 20.

34.

Are antipsychotic prescribing patterns different in older and younger adults?: a survey of 1357 psychiatric inpatients in Toronto.

Sproule BA, Lake J, Mamo DC, Uchida H, Mulsant BH.

Can J Psychiatry. 2010 Apr;55(4):248-54.

PMID:
20416148
35.

Nonmedical use of opioid analgesics among Ontario students.

Brands B, Paglia-Boak A, Sproule BA, Leslie K, Adlaf EM.

Can Fam Physician. 2010 Mar;56(3):256-62.

36.

Exploring the relationship between perceived inter-dose opioid withdrawal and patient characteristics in methadone maintenance treatment.

Elkader AK, Brands B, Callaghan R, Sproule BA.

Drug Alcohol Depend. 2009 Dec 1;105(3):209-14. doi: 10.1016/j.drugalcdep.2009.07.003. Epub 2009 Aug 26.

PMID:
19713051
37.

Methadone-nicotine interactions in methadone maintenance treatment patients.

Elkader AK, Brands B, Selby P, Sproule BA.

J Clin Psychopharmacol. 2009 Jun;29(3):231-8. doi: 10.1097/JCP.0b013e3181a39113.

PMID:
19440076
38.

Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study.

Ng W, Uchida H, Ismail Z, Mamo DC, Rajji TK, Remington G, Sproule B, Pollock BG, Mulsant BH, Bies RR.

Ther Drug Monit. 2009 Jun;31(3):360-6. doi: 10.1097/FTD.0b013e31819c7037.

PMID:
19349931
39.

Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids.

Sproule B, Brands B, Li S, Catz-Biro L.

Can Fam Physician. 2009 Jan;55(1):68-9, 69.e1-5.

40.

Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.

Elkader AK, Brands B, Dunn E, Selby P, Sproule BA.

J Clin Psychopharmacol. 2009 Feb;29(1):77-81. doi: 10.1097/JCP.0b013e318192eb00.

PMID:
19142113
41.

The impact of benzodiazepine use on methadone maintenance treatment outcomes.

Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S.

J Addict Dis. 2008;27(3):37-48. doi: 10.1080/10550880802122620.

PMID:
18956528
42.

Desvenlafaxine succinate for major depressive disorder.

Sproule BA, Hazra M, Pollock BG.

Drugs Today (Barc). 2008 Jul;44(7):475-87. doi: 10.1358/dot.2008.44.7.1227147. Review.

PMID:
18806899
43.

Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial.

Glass JR, Sproule BA, Herrmann N, Busto UE.

J Clin Psychopharmacol. 2008 Apr;28(2):182-8. doi: 10.1097/JCP.0b013e31816a9e4f.

PMID:
18344728
44.

Measuring unbound versus total valproate concentrations for therapeutic drug monitoring.

Sproule B, Nava-Ocampo AA, Kapur B.

Ther Drug Monit. 2006 Oct;28(5):714-5. No abstract available.

PMID:
17038894
45.

Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.

Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE.

BMJ. 2005 Nov 19;331(7526):1169. Epub 2005 Nov 11. Review.

46.

Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Elkader A, Sproule B.

Clin Pharmacokinet. 2005;44(7):661-80. Review.

PMID:
15966752
47.

Community pharmacists' attitudes toward and professional interactions with users of psychiatric medication.

Phokeo V, Sproule B, Raman-Wilms L.

Psychiatr Serv. 2004 Dec;55(12):1434-6.

PMID:
15572574
48.

Prescription opioid abuse in patients presenting for methadone maintenance treatment.

Brands B, Blake J, Sproule B, Gourlay D, Busto U.

Drug Alcohol Depend. 2004 Feb 7;73(2):199-207.

PMID:
14725960
49.
50.

Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly.

Felix S, Sproule BA, Hardy BG, Naranjo CA.

J Clin Psychopharmacol. 2003 Oct;23(5):471-8.

PMID:
14520124

Supplemental Content

Loading ...
Support Center